Bevacizumab combined with platinum–taxane chemotherapy as first-line treatment for advanced ovarian cancer: a prospective observational study of safety and efficacy in Japanese patients (JGOG3022 trial)

• DOI: 10.1007/s10147-018-1319-y
• Publication Date: 2018-07-20T03:50:02Z
• Authors: Shinichi Komiyama; Kazuyoshi Kato; Yuki Inokuchi; Hirokuni Takano; Takashi Matsumoto; Atsushi Hongo; Mikiko Asai-Sato; Atsushi Arakawa; Shoji Kamiura; Tsutomu Tabata; Nobuhiro Takeshima; Toru Sugiyama
• Keywords: Taxane; Surgical oncology; First line treatment

This was the first large-scale prospective observational Japanese study evaluating safety and efficacy of bevacizumab combined with paclitaxel carboplatin for newly diagnosed advanced ovarian cancer. Patients were prospectively enrolled in primary analysis cohort if they had Stage III or IV epithelial ovarian/fallopian tube/primary peritoneal cancer scheduled to receive plus every 3 weeks Cycles 1–6 2–22. Primary endpoints bevacizumab-specific adverse events ≥ Grade 3. Secondary progression-free survival (PFS) response rate. Among 346 patients enrolled, 293 formed cohort. Regarding grade 3, incidence rates thromboembolic (1.4%), gastrointestinal perforation (0.3%), fistula (0.7%), wound dehiscence (0%), bleeding (0%) very low. While hypertension (23.2%) proteinuria (12.6%) high, all such tolerable. No patient prior bowel resection developed fistula. Median PFS 16.3 months (95% CI 14.5–18.9). The rate 77.5% 67.4–85.7). 63.6% clear cell carcinoma, which tended be better than previously reported. median platinum-free interval 11.5 months, platinum-resistant recurrence 24.5%. Combining chemotherapy tolerable acceptable Bevacizumab seems reduce is promising carcinoma.